The Cooper Companies, Inc. (COO) Monthly Report
Publication Date: September 22, 2024
Company Overview
The Cooper Companies, Inc. (COO), established in 1958 and headquartered in San Ramon, California, operates within the healthcare sector, specifically in the medical instruments and supplies industry. With its two primary divisions—CooperVision and CooperSurgical—the company has carved a significant niche in the global healthcare market. CooperVision specializes in the development and marketing of a diverse range of contact lenses aimed at correcting vision problems, while CooperSurgical focuses on women’s and family health care, providing critical products and services related to fertility, medical devices, and contraception.
Investment Opportunity
Current market dynamics indicate that the Medical Instruments and Supplies industry offers a compelling investment opportunity, prompting a “buy” recommendation for Cooper Companies, Inc. The firm’s total revenue is approximately $3.8 billion, accompanied by a current stock price of $110.49. Analysts have set a target high price of $125.00, reflecting optimistic projections for the company’s performance. Additionally, the target mean price is estimated at $113.01. The robust revenue figures combined with an encouraging price outlook suggest that investors have a viable entry point into the market.
Investors should note that the company has 199,156,000 shares outstanding, with about 2,018,496 shares currently shorted, which constitutes approximately 1.15% of the float. This low short interest signals a moderate level of bearish sentiment, affording a cautious yet optimistic view of the stock.
Market Performance Metrics
With a current stock price of $110.49, Cooper Companies is nearing its fifty-two week high of $112.38, signifying strong performance over the past year. The fifty-day average sits at $97.633, indicating that the stock has consistently traded above this recent average, demonstrating positive momentum. The fifty-two week low of $75.935 showcases a remarkable recovery and underscores market confidence in the stock’s potential.
Given the estimated price range—with a target high of $125.00 and a target low of $95.09—the potential for upward movement is substantial. The mean recommendation score of 2.1 from 14 analysts indicates a supportive consensus regarding the stock’s growth prospects. Such encouraging metrics reinforce the attractiveness of this stock for potential investors looking for quality opportunities within the healthcare sector.
| Metric | Value |
|---|---|
| Market Cap | $22.0b |
| Total Debt | $2.9b |
| Total Cash | $109.7m |
| Shares Outstanding | 199.2m |
| Float Shares | 197.9m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.